News
10/14/2016

Preliminary Announcement: an international call in Nanomedicine to be open soon

The French National Research Agency, in partnership with 18 countries is set to launch a 8th joint transnational call for proposals through the ERA-NET EuroNanoMed (ENM) on Nanomedicine. The call is likely to open on November 14th.

The goal of this call for proposals is to both support translational research projects that combine innovative approaches in the field of Nanomedicine and to encourage and enable transnational collaboration between public and private research groups from academia, clinical/public health research or research teams from industrial enterprises (all sizes). The participation of Medical Doctors and SMEs will be strongly encouraged. This call for proposals includes funding research organisations of 19 countries (Belgium, Canada, Estonia, France, Germany, Greece, Ireland, Israel, Italy, Latvia, Lithuania, Netherlands, Norway, Poland, Romania, Slovakia, Spain, Taiwan, and Turkey) and should be allowed of global budget of M€14.

Three encouraged topics

Project proposals will need to cover at least one of the following areas that are equal in relevance for this call: regenerative medicine, diagnostics, targeted delivery systems.

The projects should fall within Technology Readiness Levels (TRL)  3-6, although for being realistic and coherent with the characteristics of the call, projects should propose advancements for a maximum of two TRL levels during their lifetime.

Consortium composition

A consortium applying to this call will be required to include research group(s) from at least 2 of the 3 following categories:

  • Academia (research teams working in universities, other higher education institutions or research institutes);
  • Clinical/public health sector (research teams working in hospitals/public health and/or other health care settings and health organisations). Participation of Medical Doctors is encouraged;
  • Enterprise (all sizes of private companies). Participation of small and medium-size enterprises (SMEs) will be encouraged.

Only transnational projects will be funded. Each consortium submitting a proposal will need to involve a minimum of 3 eligible and a maximum of 5 eligible partners from at least 3 different countries participating to the call. The project coordinator must be eligible to be funded by EuroNanoMed III participating countries/regions. No more than 2 eligible partners from the same country participating in the call will be accepted in one consortium.

Research groups not eligible to be funded (e.g. from non-funding countries or not fundable according to national/regional regulations of the participating funding countries) may participate in transnational projects if they are able to secure their own funding. However, no more than one research group with own funding can be included.

The maximum number of partners will possibly be increased from 5 to 7 (including eligible for funding and non-eligible for funding research groups) if partners from these participating countries, which are either new in the EuroNanoMed consortium or their community has been under-represented in past EuroNanoMed calls: Belgium, Estonia, Ireland, Latvia, Lithuania, Romania, Slovakia, Taiwan, and Turkey (see table below).

  • Consortium contenant des partenaires en provenance de pays nouveaux dans l’ERA-NET,
  • Consortium contenant des partenaires en provenance de pays sous-représentés lors d’appels précédents (Belgique, Estonie, Irlande, Lettonie, Lituanie, Roumanie, Slovaquie, Taiwan ou Turquie.
Number of partners requesting funding (eligible partners)3456
(only with at least
one underrepresented/new)
7
(only with at least 2 underrepresented/new)
Possible number of additional partners with own funding11110

 

Estimated schedule:

  • This call is likely to open on:                    14th November 2016
  • Submission deadline for pre-proposals:  16th January 2017
  • Submission deadline of full proposals:    9th June 2017

More details:

Last updated on 29 January 2019
Sign up for the latest news:
Subscribe to our newsletter